Formulation Strategies for Protein Therapeutics
CSS
Event Information
Alternate Language Options:
September 21 - 23, 2010 · Rhode Island Convention Center · Providence, RI
Document Title
Event Overview
Practical, Focused Strategies for Formulation Scientists from Around the World
Particles, Particles Everywhere: Causes, Consequences and Control of Aggregates and Subvisible Particles in Therapeutic Protein Formulations
John F. Carpenter, Ph.D., Professor, Department of Pharmaceutical Sciences, University of Colorado
Holistic QbD: The Integration of Formulation, Process Development and Process Validation
Sherry Martin Moe, Ph.D., Director, Late Stage Pharmaceutical and Processing, Development, Genentech, Inc.
NIST Perspective on Standards and GMP Processes for Subvisible Particles in Protein Therapeutics
Dean Ripple, Ph.D., Group Leader, Process Measurements Division, Process Sensing Group, National Institute of Standards and Technology
Modeling Protein Degradation Processes and the Development of Rational Approaches to Stabilization
Bernhardt Trout, Ph.D., Professor, Chemical Engineering, Massachusetts Institute of Technology
The program agenda for the 10th anniversary of IBC's Formulation Strategies for Protein Therapeutics reflects the changes in our industry and their impact on the formulation function. Novel therapeutics, new regulatory requirements, advanced analytical instrumentation and the need to develop more patient-convenient delivery methods are changing the day to day work of the formulation scientist.
By attending this meeting, you will learn about next generation approaches to formulation and learn how colleagues from around the world are employing technology and new knowledge of protein behavior to optimize and accelerate formulation development.
2010 Program Highlights:
Merck Research Laboratories details a case study showing the need to apply orthogonal methods to characterize and evaluate aggregates and subvisible particles in biological formulations.
- Genentech outlines a model for identifying oxidation sites and screening stabilizers that reveal methods for protecting proteins from oxidation
- GlaxoSmithKline illustrates a development project that considers the relationship between biopharm product formulation parameters and the functionality features of a proposed container and delivery system
- ImClone Systems demonstrates its approach to the integration of multiple complex datasets to resolve the challenges of formulation development and protein characterization
- The University of Kansas examines the utility and limitations of analytical methods used to detect key degradants in formulation and container closure development
- Seattle Genetics explores a case study of a novel antibody-drug conjugate (ADC) that considers the general development strategy for antibodies and the unique challenges posed by an ADC in developing a lyophilized formulation
Held concurrently with IBC's BioProcess International™ Conference and Exhibition, September 20-24, 2010, Formulation delegates have access to the BPI exhibit floor, posters, keynotes and social functions, giving you the opportunity to visit with more than 125 suppliers of bioprocess technology and services and network with over 1,500 colleagues and industry leaders.
» See Who You Will Meet at BPI & Formulation This Year
Here what past attendees had to say....
"Great job on the planning and execution of conference. Very helpful, also great to meet people in the field."
- Jonathan Clapper, Senior Research Associate, Process Development, Trubion
"The Formulation Strategies conferences provided a comprehensive road map to state of the art formulation opportunities and challenges. It provided a snapshot of the latest industry challenges and methods to address these challenges."
- David Hile, Senior Scientist, Formulation Development, Stryker Biotech
"The IBC conference is a unique opportunity to get an overview of the latest developments in protein formulation with the technical experts from the biotech industry"
- Sylvan Huille, Department Head, Formulation Development, LFB France
"Case studies and specific examples are most helpful to the formula scientist for benchmarking purposes. I appreciated the high number of such presentations at this conference. The interactive breakout sessions were beneficial as well for benchmarking purposes"
- Susan Martin, Senior Principal Scientist, Biologics PGRD, Pfizer
"I commend the IBC staff for putting together a balanced mix of topics including emerging areas in biotherapeutics formulation development and a problem solving session."
- Tapan Das, Ph.D., Senior Principal Scientist, Pfizer Global Biologics
"The conference is a good learning experience for formulation starters - it is excellent overview for starter companies."
- Harold Backus, Manager, Analytical Development, Crucell, The Netherlands
"The conference had outstanding presentations and good discussions. The round table and panel discussions are very useful."
- Nazila Miller, Scientist, PAD, Shire Human Genetic Therapies
"I came to this conference as a relative novice in the formulation field. It was helpful and educational to have topics that were general as well as case studies, to highlight real world problems encountered by formulations researchers."
